Yale Jen analyst LAIDLAW

Currently out of the existing stock ratings of Yale Jen, 18 are a BUY (100%).

Yale Jen

Work Performance Price Targets & Ratings Chart

Analyst Yale Jen, currently employed at LAIDLAW, carries an average stock price target met ratio of 50.28% that have a potential upside of 103.17% achieved within 188 days.

Yale Jen’s has documented 36 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on AFMD, Affimed NV at 13-Jun-2024.

Wall Street Analyst Yale Jen

Analyst best performing recommendations are on CRIS (CURIS).
The best stock recommendation documented was for CRIS (CURIS) at 12/8/2020. The price target of $10 was fulfilled within 31 days with a profit of $3.45 (52.67%) receiving and performance score of 16.99.

Average potential price target upside

ARCT Arcturus Therapeutics Holdings CRIS Curis VINC Vincerx Pharma IONS Ionis Pharmaceuticals EVFM Evofem Biosciences TCRT Alaunos Therapeutics SLNO Soleno Therapeutics AFMD Affimed NV

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$63

$39.12 (163.82%)

$63

4 days ago

14/27 (51.85%)

$37.75 (149.50%)

165

Buy

$54

1 months 29 days ago

3/5 (60%)

$21.39 (65.59%)

559

Buy

$86

$62.12 (260.13%)

$87

4 months 25 days ago

1/3 (33.33%)

$58.74 (215.48%)

75

Buy

$48

$24.12 (101.01%)

$40

7 months 27 days ago

4/8 (50%)

$10.09 (26.62%)

195

Buy

$36

1 years 2 months 21 days ago

2/2 (100%)

$15.83 (78.48%)

271

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Yale Jen is most bullish on?

Potential upside of $21.79 has been obtained for AFMD (AFFIMED NV)

What Year was the first public recommendation made by Yale Jen?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?